Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: Aug 6, 2025
Enrollment Complete in Cohorts 1 and 2 of MyPEAK™-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts
Read more at globenewswire.com1.23
+0.07 (+6.03%)
Find more stocks in the Stock Screener
TNYA Latest News and Analysis
